TheraRadar
Data updated: Mar 29, 2026

NEODECADRON

DEXAMETHASONE SODIUM PHOSPHATE
Approved 1969-07-02
Jump to: Indications Approvals Trials Competitors Safety Patents
4
Indications
--
Phase 3 Trials
56
Years on Market

Details

Status
Discontinued
First Approved
1969-07-02
Routes
OPHTHALMIC
Dosage Forms
OINTMENT, SOLUTION/DROPS

Companies

Merck
Active Ingredient: DEXAMETHASONE SODIUM PHOSPHATE , NEOMYCIN SULFATE

NEODECADRON Approval History

Loading approval history...

What NEODECADRON Treats

4 FDA approvals

Originally approved for its first indication in 1969 . Covers 4 distinct patient populations.

  • Other (4)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NEODECADRON FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA050324 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.